Royalty Report: Drugs, Tobacco, Pharmaceuticals – Collection: 1479


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Tobacco
  • Pharmaceuticals
  • Delivery
  • Therapeutic
  • Chemicals
  • Nicotine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1479

License Grant
The Company sold its nicotine technology and related assets; Nicotrol/Nicorette Inhaler (the 'Inhaler') for use in the nicotine replacement therapy; nicotine vapor inhaler device for use in the smoking cessation industry.
License Property
The technology is a nicotine vapor inhaler designed to satisfy nicotine cravings and give the reforming smoker the feeling of holding a cigarette.

IPSCIO Record ID: 2048

License Grant
The Company has the right to product using a nicotine impermeable copolymer technology covered by, and subsequent to, the issuance of a patent in March 1996; receives royalties from the sales of the Nicorette/Nicotrol patch.

IPSCIO Record ID: 570

License Grant
The Company shall sell, assign, transfer, convey and deliver to Purchaser, and Purchaser shall purchase, acquire and accept from the Company, all of the Company's right, title and interest in and to those certain assets  (the 'Intellectual Property').
License Property
The Company has developed and owns the certain Intellectual Property which it refers to as the 'U-Strip' Technology.

The technology refers to certain intellectual property encompassing a new type of non-invasive drug delivery system more commonly known as a transdermal patch.

Passive drug delivery patches have applications including smoking cessation (nicotine), birth control and hormone replacement therapy (estradiol), and angina (nitroglycerine). By contrast, active transdermal drug delivery systems allow certain drugs to be delivered through the skin many times faster than passive transdermal patches.

IPSCIO Record ID: 26307

License Grant
The Licensor hereby grants to Dutch corporation an exclusive license under Licensor Patent Rights in the Licensed Territory for Licensed Products in the Field of Use.  The Licensor has Licensed and further developed a technology for the purpose of removing substances from cigarette smoke.  The Dutch licensee produced the chemical compound for the filter.
License Property
Territory and Patents Europe  – Patent Application EP 00941705.6 – entering National Phase in January 2007

China – Patent CN1271960C
Canada – Patent Application CA2414377
Mexico – Patent Application MXPA03000125
Japan – Patent Application JP2004500901T
Brazil – Patent Application BR0017258
PCT – Patent Application WO0200046

This invention relates generally to methods, devices and agents for the removal of nucleophilic toxins present in tobacco and tobacco smoke, without affecting nicotine delivery. Nucleophilic toxins are removed by the passage of tobacco smoke or air containing tobacco smoke through a nucleophilic toxin-removing filter device. Agents may also be incorporated into smoking and smokeless tobacco to prevent volatilization and absorption, respectively, of nucleophilic toxins. Dosimetry of nucleophilic tobacco combustion products is used to monitor toxin exposure.

The technology fundamental to Licensee is protected under U.S. Patent number 6,119,701, entitled 'Methods, agents and devices for removing nucleophilic toxins from tobacco and tobacco smoke'.   This invention provides methods, devices and agents for the removal of nucleophilic toxins present in tobacco and tobacco smoke, without the removal of nicotine. The filter element of a tobacco smoking device or an air filtration device used in conjunction with a tobacco smoking device may comprise chemical moieties reactive with nucleophilic compounds, or agents that trap nucleophilic compounds may be incorporated into the filter element of tobacco smoking device such as a cigarette, cigar, pipe, or in a separate filter through which tobacco smoke passes before entering the mouth. The agents may also be incorporated into air filters for removing tobacco combustion product toxins from room air. The agents may also be incorporated into smoking or smokeless tobacco to remove toxins.

IPSCIO Record ID: 28258

License Grant
The Company entered into an exclusive license agreement with a University to assist in the development of the Nicotine Receptor Agonist technology.  The Licensee has exclusive worldwide licensing rights to develop, manufacture, use and sell products incorporating nicotine and nicotine agonists for therapeutic angiogenesis.
License Property
Nicotine Receptor Agonist technology promotes new growth of blood vessels (known as angiogenesis or vasculogenesis), and has applications in the treatment of heart disease, stroke, limb circulatory disease, and wound healing.

IPSCIO Record ID: 315809

License Grant
Licensor grants under the Licensor Technology in the U.S.
–   an exclusive license, with the right to sublicense, to research, develop, import, use, market, sell, have sold, offer for sale and otherwise commercialize the Product in the Field in the U.S., and
–   a co-exclusive license, with the right to sublicense, to manufacture and have manufactured the Product for the purposes of researching, developing, importing, using, marketing, selling, having sold, offering for sale and otherwise commercializing the Product in the Field in the U.S.; and,
–   a non-exclusive license, with the right to sublicense, solely and to the extent needed to conduct clinical and non-clinical development activities with respect to the Product in the Field outside the U.S.
License Property
Licensor is a pharmaceutical development company focused on the research, development, manufacturing and commercialization of novel proprietary products for the acute treatment of central nervous system disorders based on its proprietary technology, the Staccato® system, and has developed and obtained FDA approval for a drug-device combination product that is comprised of Loxapine (as defined hereinafter) delivered by a Staccato Device, and approved under the trade name Adasuve. Licensor owns or controls certain patents, know-how and other intellectual property relating to the Staccato Device and Product.

Product shall mean the drug-device combination product that is comprised of Loxapinc delivered by the Staccato Device, which has been or is during the Term approved by the FDA in the U.S., which form of product is currently designated as Adasuve®.

Staccato Device shall mean any hand-held, fixed-dosage device for the administration of API(s), which relies on Licensors proprietary heat package and stainless steel substrate to rapidly heat and create a condensation vaporized aerosol of APl(s) that allows the delivery of API(s) through deep lung inhalation, where the device is known as or based on, but may or may not be referred to, as the Staccato® system.

The patents relate to the Delivery of antipsychotics through an inhalation route.

Field of Use
ADASUVE (loxapine) is an inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

IPSCIO Record ID: 147203

License Grant
The Original Agreement which granted Company a license to make, have made, use and sell certain products, subject to certain payment obligations from Company to Party B and the University, with certain sublicense rights shall be amended.
License Property
Technology shall mean any knowledge, information, knowhow and devices, whether patentable or not, in the possession of Party B relating to

(i)      use of cotinine for body weight management, including but not limited to US. Patent Application/Serial No. 07/964,277, filed October 21, 1992, and issued as U.S. Patent No. 5,643,928, and corresponding foreign patent applications or patents listed;

(ii)     therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine, including but not limited to U.S. Patent Application/Serial No. 07/885,314, filed May 18, 1992, and issued as U.S. Patent No. 5,596,007, and corresponding foreign patent applications or patents listed

(iii)    use of cotinine to assist in the cessation of tobacco smoking, including but not limited to U.S. Patent Application/Serial No. 07/971,573, filed November 5, 1992, and corresponding foreign patent applications listed;

(iv)     use of cotinine to assist in the cessation of tobacco smoking, including but not limited to U.S. Patent Application/Serial No. 08/293,585, filed August 22, 1994, and issued as U.S. Patent No. 5,612,357, and corresponding foreign patent applications or patents listed; and

(v)      use of cotinine to alleviate tobacco withdrawal syndrome, including but not limited to U.S. Patent Application/Serial No. 08/691,888, filed August 1, 1996, and issued as U.S. Patent No. 5,747,512, and corresponding foreign patent applications or patents listed.

Phase I Studies shall mean pilot efficacy studies.

Field of Use
This agreement pertains to the drug industry relating to body weight management and tobacco usage.

IPSCIO Record ID: 300758

License Grant
The Canadian Licensor grants an exclusive, worldwide license, including the exclusive right to sub-license, to Commercially Exploit Intellectual Property covered by all or any part of the Patent Rights in the Field.
License Property
Licensor has certain information and intellectual property related to alkaloid biosynthesis in Nicotiana plants or products made from the tobacco plant.

The patents include
Nucleic Acid Sequences and Their Use in Modifying Alkaloid Production in Plants,
Methods of Modifying Alkaloid Production in Plants,
Nucleic Acid Encoding N-methylputrescine Oxidase and Uses Thereof, and,
Nucleic Acid Sequences Encoding Transcription Factors Regulating Alkaloid Biosynthesis and Their Use in Modifying Plant Metabolism.

Field of Use
Licensor believe the proprietary technology provides it with opportunities in the global market for approved smoking cessation aids and the emerging market for modified risk tobacco products

Licensor  is a plant biotechnology company and a global leader in modifying the content of nicotinic alkaloids in tobacco plants through genetic engineering and plant breeding.

The Field means all uses of Nicotiana plants and products produced therefrom.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.